Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Gynecol Pathol ; 40(5): 482-486, 2021 Sep 01.
Article in English | MEDLINE | ID: mdl-33252403

ABSTRACT

Pilomatrix carcinoma (PC) is a rare malignant variant of pilomatrixoma, a skin adnexal tumor originating from hair matrix cells. It is most often located in the head, neck region, upper back and upper extremities. PC has a locally aggressive behavior but metastasis only occur in 10% of cases. Mutations in CTNNB1, the encoding gene of beta-catenin, have been found in both pilomatrixoma and PC, but other molecular alterations are unknown. The authors present a case of PC in the clitoris, the third known reported case located on the external genitalia. The tumor followed an unusual clinical course with the development of multiple metastases. Next-generation sequencing analysis of the tumor identified, in addition to a characteristic CTNNB1 mutation, pathogenic mutations in PTEN, PIK3CA, and ARID1A, which could explain the aggressive course of the disease. The diagnostic criteria of PC and the differential diagnoses of this unusual tumor in the genital area are discussed.


Subject(s)
Hair Diseases/diagnosis , Pilomatrixoma/diagnosis , Skin Neoplasms/diagnosis , Vulvar Neoplasms/diagnosis , beta Catenin/genetics , Diagnosis, Differential , Female , Hair Diseases/genetics , Hair Diseases/pathology , High-Throughput Nucleotide Sequencing , Humans , Middle Aged , Mutation , Pilomatrixoma/genetics , Pilomatrixoma/pathology , Sequence Analysis, DNA , Skin Neoplasms/genetics , Skin Neoplasms/pathology , Vulva/pathology , Vulvar Neoplasms/genetics , Vulvar Neoplasms/pathology
2.
Mod Rheumatol Case Rep ; 4(2): 318-323, 2020 07.
Article in English | MEDLINE | ID: mdl-33087005

ABSTRACT

A 59 year-old woman was treated with adjuvant chemotherapy for triple negative breast cancer (TNBC) stage IB. She received pegfilgrastrim as secondary prophylaxis of neutropenia. After administration of pegfilgrastrim on day 11, she was hospitalised because of carotidynia and myocarditis that improved with antibiotics and steroids as an infection was suspected. Once she was recovered, another cycle of chemotherapy with pegfilgrastrim was administrated. At this time, the patient presented to our hospital with fever, odynophagia and chest pain, with diagnosis of myocarditis coupled with cardiogenic shock. She received antibiotics and steroids, advanced life support and also a pericardial window was done, with recovery of her condition. After a complete evaluation and exclusion of other possible aetiologies, we concluded that pegfilgrastrim was responsible for inducing carotidynia and myocarditis. Few cases have been published about Granulocyte-Colony stimulating factor (G-CSF) induced carotidynia and aortitis. However, this is the first reported case about G-CSF induced myocarditis and carotidynia.


Subject(s)
Aortitis/diagnosis , Aortitis/etiology , Granulocyte Colony-Stimulating Factor/adverse effects , Myocarditis/diagnosis , Myocarditis/etiology , Anti-Bacterial Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Female , Filgrastim/administration & dosage , Filgrastim/adverse effects , Granulocyte Colony-Stimulating Factor/administration & dosage , Humans , Middle Aged , Neutropenia/drug therapy , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/adverse effects , Steroids/therapeutic use , Treatment Outcome , Triple Negative Breast Neoplasms/complications , Triple Negative Breast Neoplasms/drug therapy
3.
Cancer Manag Res ; 11: 4541-4548, 2019.
Article in English | MEDLINE | ID: mdl-31191015

ABSTRACT

Immune checkpoint inhibitors have revolutionized cancer treatment due to their undeniable efficacy, but a range of new adverse events (AE) has emerged. In particular, cardiac toxicity is a potentially fatal AE, and introduces new challenges regarding its underlying molecular mechanisms of occurrence, optimal treatment and follow up, and prevention. We present a clinical case of a patient with advanced kidney cancer treated with nivolumab as a third line treatment. After four cycles, the patient developed nonspecific symptoms and was hospitalized, identifying a set of clinical, analytical and electrocardiographic alterations compatible with myocarditis. Despite the intensive support, the patient died and a necropsy study was performed. We present a detailed description of the clinical case including the pathological and molecular findings, and we conduct a review of the available evidence related to immune-mediated cardiac toxicity to offer some new highlights in the management of this AE.

SELECTION OF CITATIONS
SEARCH DETAIL
...